Insider Sale: Heng Fai Chan Disposes 130,679 DSS Shares at $1.35 Avg
Rhea-AI Filing Summary
Insider sale disclosed. On 08/28/2025, Heng Fai Ambrose Chan reported selling 130,679 shares of DSS, Inc. common stock at an average price of $1.3475, with trade prices ranging between $1.23 and $1.565. The Form 4 states the sale occurred in multiple trades and the reporting person undertakes to provide full trade-by-trade details upon request.
The filing reports 1,053,796 shares beneficially owned by Mr. Chan following the transaction and identifies additional holdings attributed to him: 1,002,978 shares held by Heng Fai Holdings Limited; 2,581,268 shares held by Alset Inc.; a $500,000 convertible promissory note held by Alset Inc.; 1,068,309 shares held by Alset International Limited; and 311,634 shares held by Global Biomedical Pte. Ltd. The Form 4 is signed 09/02/2025.
Positive
- Transparent disclosure of the sale date, number of shares sold, average price, and price range
- Undertaking to provide full trade details upon request enhances regulatory transparency
- Detailed breakdown of beneficial ownership across controlled entities and convertible note
Negative
- Insider sale of 130,679 shares reported on 08/28/2025 which reduces the reporting person's direct holdings
- Concentration of shares across related entities indicates significant insider exposure that could affect perceptions of insider liquidity needs
Insights
TL;DR: Insider disposition of 130,679 shares at ~$1.35 reported; significant affiliated holdings remain disclosed.
The transaction is a clear disclosure of a modest insider sale relative to the aggregated holdings disclosed. The sale quantity (130,679 shares) and average price ($1.3475) are explicit and accompanied by a price range, which aids transparency. Material aggregated holdings across related entities are sizeable and explicitly listed, indicating continued substantial insider economic exposure despite this sale. Impact on valuation or control cannot be assessed from this single sale alone.
TL;DR: Form 4 shows compliant disclosure of an insider sale with detailed beneficial ownership across controlled entities.
The filing conforms to Section 16 reporting by specifying the sale date, shares sold, average sale price, and a willingness to provide trade-level details on request. The reporting person checks both Director and 10% owner boxes, and the explanation enumerates multiple controlled entities and instruments that constitute beneficial ownership. This level of disclosure supports governance transparency for shareholders monitoring insider activity.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 130,679 | $1.3475 | $176K |
Footnotes (1)
- On August 28, 2025, Mr. Chan sold 130,679 shares of the Issuer's common stock at an average sale price of $1.3475. The shares were sold in multiple trades at prices ranging between $1.23 and $1.565. The reporting person hereby undertakes to provide, upon request of the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. The beneficial ownership of Mr. Chan may be deemed to include the following: (a) 1,002,978 shares of the Issuer's common stock held by Heng Fai Holdings Limited, an entity controlled by Heng Fai Chan; (b) 1,053,796 shares of the Issuer's common stock held by Mr. Chan directly; (c) 2,581,268 shares of the Issuer's common stock held by Alset Inc., an entity controlled by Mr. Chan; (d) a convertible promissory note in the amount of $500,000 held by Alset Inc. and convertible into shares of the Issuer's common stock; (e) 1,068,309 shares of the Issuer's common stock held by Alset International Limited, an entity controlled by Mr. Chan and a subsidiary of Alset Inc.; and (f) 311,634 shares of the Issuer's common stock held by Global Biomedical Pte. Ltd., an entity controlled by Mr. Chan and a subsidiary of Alset International Limited (which is a subsidiary of Alset Inc.).
